SCHEMBL8007192

SCHEMBL8007192

COc1nc(N)c(Cl)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
CD44 P16070 1/20 0.35
NPC1 O15118 2/20 0.35
GAA P10253 1/20 0.35
POLB P06746 3/20 0.35
HSP90AA1 P07900 3/20 0.35
HSP90AB1 P08238 2/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
RAD52 P43351 1/20 0.33
UBE2N P61088 1/20 0.33
CYP3A4 P08684 1/20 0.33
RECQL P46063 1/20 0.33
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8004058 0.81 POLB (0.38) GSK3AGSK3BDYRK1ACLK4POLB
SCHEMBL21372397 0.79 CYP3A4 (0.37) GSK3AGSK3BDYRK1ACLK4CD44
SCHEMBL26927378 0.78 GSK3A (0.39) GSK3AGSK3BDYRK1ACLK4NPC1
SCHEMBL31500457 0.78 GSK3A (0.39) GSK3AGSK3BDYRK1ACLK4NPC1
SCHEMBL8000890 0.76 POLB (0.36) GSK3AGSK3BDYRK1ACLK4POLB
SCHEMBL20355369 0.76 PIK3CA (0.37) GSK3AGSK3BDYRK1ACLK4NPC1
SCHEMBL8004061 0.76 POLB (0.35) GSK3AGSK3BDYRK1ACLK4POLB
SCHEMBL7779192 0.74 CFTR (0.40) GSK3AGSK3BDYRK1ACLK4CYP3A4
SCHEMBL24455092 0.74 CD44 (0.41) CD44POLBKMT2AKDM4EALDH1A1
SCHEMBL6331409 0.73 POLB (0.47) GSK3AGSK3BDYRK1ACLK4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2256114-B1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAINIPPON SUMITOMO PHARMA CO (JP) 2014-06-25 EP disclosed
US-7906510-B2 Amide derivative and pharmaceutical composition containing the same Dainippon Sumito Pharma Co., Ltd. (JP) 2011-03-15 US disclosed
US-7906510-B2 Amide derivative and pharmaceutical composition containing the same Dainippon Sumito Pharma Co., Ltd. (JP) 2011-03-15 US disclosed
EP-2256114-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Dainippon Sumitomo Pharma Co., Ltd. (JP) 2010-12-01 EP disclosed
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Sumitomo Pharma Co., Ltd. (JP) 2010-09-30 US disclosed
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Sumitomo Pharma Co., Ltd. (JP) 2010-09-30 US disclosed
WO-2009104729-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME 大日本住友製薬株式会社 (JP) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249399-A1 AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME HTR4, MC2R, HTR1D GSK3A 4141/4885GSK3B 4238/4885DYRK1A 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.